United States: WilmerHale Counsels Syros Pharmaceuticals In $35M Private Placement
Last Updated: May 3 2017

Syros Pharmaceuticals, a biopharmaceutical company pioneering the discovery and development of medicines to control the expression of disease-driving genes, announced that it has entered into a stock purchase agreement with several institutional accredited investors for the private placement of 2,592,591 shares of common stock at a purchase price of $13.50 per share, yielding expected gross proceeds of $35 million.

The WilmerHale team counseling Syros included Steven Singer, Cynthia Mazareas, Mhairi Immermann, and Killian Nolan.

Read Syros Pharmaceuticals' press release for more information.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

 
Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Press Releases from this Firm
Recent Content from this Firm
By Gary Born
By Leila Gaafar
By Timothy Silva, Seth Davis
By Christopher Babbitt, Jonathan Bressler, Claire Chung
By WilmerHale
By Jonathan Yarowsky, Perry A. Lange, Hartmut Schneider, Leon Greenfield, D. Reed Freeman, Jr., Heather Zachary
By Jay Holtmeier, Erin Sloane
By Geoffroy Barthet, Nicole Callan, Cormac O'Daly, Hartmut Schneider
By WilmerHale
By WilmerHale
Tools
Print
Font Size:
Translation
Channels